Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.

Ishii, Nobuya; Harada, Naoki; Joseph, Eric W; Ohara, Kazuhiro; Miura, Takaaki; Sakamoto, Hiroshi; Matsuda, Yutaka; Tomii, Yasushi; Tachibana-Kondo, Yukako; Iikura, Hitoshi; Aoki, Toshihiro; Shimma, Nobuo; Arisawa, Mikio; Sowa, Yoshihiro; Poulikakos, Poulikos I; Rosen, Neal; Aoki, Yuko; Sakai, Toshiyuki

Ishii, Nobuya; Harada, Naoki; Joseph, Eric W; Ohara, Kazuhiro; Miura, Takaaki; Sakamoto, Hiroshi; Matsuda, Yutaka; Tomii, Yasushi; Tachibana-Kondo, Yukako; Iikura, Hitoshi; Aoki, Toshihiro; Shimma, Nobuo; Arisawa, Mikio; Sowa, Yoshihiro; Poulikakos, Poulikos I; Rosen, Neal; Aoki, Yuko; Sakai, Toshiyuki.

Affiliation

Ishii N; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Harada N; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Joseph EW; Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York.
Ohara K; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Miura T; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Sakamoto H; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Matsuda Y; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Tomii Y; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Tachibana-Kondo Y; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Iikura H; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Aoki T; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Shimma N; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Arisawa M; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Sowa Y; Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Poulikakos PI; Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York.
Rosen N; Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York.
Aoki Y; Kamakura Research Laboratory, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
Sakai T; Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Cancer Res ; 73(13): 4050-4060, 2013 Jul 01.

Article de En | MEDLINE | ID: mdl-23667175

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Coumarines / Système de signalisation des MAP kinases / Protéines proto-oncogènes B-raf / MAP Kinase Kinase 1 / Antinéoplasiques Limites: Animals / Female / Humans Langue: En Journal: Cancer Res Année: 2013 Type de document: Article Pays d'affiliation: Japon Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google